

Vanda Strikes Out at the Supreme Court



LESS THAN 1 MIN READ

April 22, 2024, 3:57 PM

By: Matthew S. Murphy, Thomas K. Hedemann

Two weeks ago we discussed Vanda Pharmaceuticals' ambitious cert petition asking the Supreme Court to discontinue the "reasonable expectation of success" standard for patent obviousness that for decades has been a mainstay of patent law.

Vanda argued that the Court should instead adopt a "predictable results" standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda's petition, leaving the obviousness standard unchanged.



Related People



Matthew S. Murphy



Thomas K. Hedemann

Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

TAGS

generics

News & Insights

- Stakeholders 24th Annual CYOC Career Development Conference
SPONSORSHIP
- CompLaw 33rd Annual Advanced EU Brussels Conference
SPEAKING ENGAGEMENT
- ALM General Counsel Conference East 2024
SPEAKING ENGAGEMENT ANTITRUST
- Global Legal Group Global Class Actions Symposium 2024
SPEAKING ENGAGEMENT LITIGATION & TRIALS
- NAPABA Convention 2024
SPONSORSHIP
- Kisaco Research Pharma and Biotech Patent Litigation 2024
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- AIJA IP/TMT Seminar // 11th Antitrust Annual Conference
SPEAKING ENGAGEMENT ANTITRUST
- EDTX Bench Bar Conference 2024
SPONSORSHIP ANTITRUST

- Informa Connect Antitrust Texas Conference 2024
SPEAKING ENGAGEMENT ANTITRUST
- LSPN North America Fall Conference 2024
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY

© 2024 Axinn, Veltrop & Harkrider LLP. All Rights Reserved